Abstract
BackgroundTo circumvent some pitfalls related to acute status, chronic model of asthma is conceived to be more suitable approach to guarantee the conditions which are similar to human pulmonary disease. Here, possible therapeutic mechanisms were monitored by which c-kit+ bone marrow cells can attenuate vascular inflammation in rat model of chronic asthma.ResultsData revealed c-Kit+ cells could significantly reduce pathological injures in asthmatic rats via modulating the expression of IL-4, INF-γ, ICAM-1 and VCAM-1 in lung tissues and TNF-α, IL-1β and NO levels in BALF (p < 0.001 to p < 0.05). Besides, c-Kit+ cells reduced increased levels of VCAM-1 evaluated by immunohistochemistry staining. In contrast to c-Kit+ cells, c-Kit− cells could not exert beneficial effects in the asthmatic conditions.ConclusionOverall, we found that systemic administration of C-kit positive cells can diminish pulmonary and vascular inflammation of chronic asthmatic changes in a rat model. These cells are eligible to suppress inflammation and nitrosative stress in lung tissue coincides with the reduction of pathological changes. These data indicate that C-kit positive cells be used as an alternative cell source for the amelioration of asthmatic changes.
Highlights
To circumvent some pitfalls related to acute status, chronic model of asthma is conceived to be more suitable approach to guarantee the conditions which are similar to human pulmonary disease
C‐Kit+ cells are eligible to attenuate pathological remodeling during asthmatic changes H & E examination displayed that chronic asthma was successfully induced in rats (Fig. 3, Table 2)
We found that the intensity of interstitial pneumonitis, focal hyperemia, atelectasis, fibrosis, bronchiolar epithelial cell injury and goblet cell proliferation were diminished in asthmatic rats received c-Kit+ cells
Summary
To circumvent some pitfalls related to acute status, chronic model of asthma is conceived to be more suitable approach to guarantee the conditions which are similar to human pulmonary disease. The occurrence of asthma can lead to debilitating pathological condition of lung tissue which is mainly characterized by prominent airway conduit inflammation. These conditions affect over 400 million individuals globally with limited therapeutic options [1, 2]. Regarding the entity of asthma and complexity of pathological pattern, it seems that the regeneration of injured and inflamed pulmonary tissue via conventional medications is not completely feasible [7,8,9] In this context, Most efforts have been targeted at the discovery of de novo therapeutic agents in asthmatic patients from the past to the present time [2, 7, 8, 10]. Among multiple sets of stem cells and progenitors have been applied for different diseases, c-Kit positive cells are not routinely administrated for chronic asthma
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
